New Delhi: Bharat Parenterals Limited’s subsidiary, Innoxel Lifesciences, has announced the successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection conducted by Belgium’s Federal Agency for Medicines and Health Products (FAMHP).
The inspection, held at the company’s state-of-the-art manufacturing facility from 24th to 28th November 2025, concluded with zero critical and zero major observations. This outcome highlights Innoxel’s robust quality systems, advanced manufacturing infrastructure, and unwavering compliance with international regulatory standards.
This milestone adds to the company’s growing list of regulatory achievements, following its earlier successful USFDA inspections, and further strengthens its position as a trusted partner in regulated global markets.
The company’s management expressed pride in the achievement, stating: “Successfully completing the EU GMP inspection by the FAMHP, Belgium with zero critical and zero major observations is a testament to our teams’ dedication to quality and compliance. This achievement enhances our ability to serve regulated markets and supports our long-term strategic growth objectives.”
Bharat Parenterals and Innoxel Lifesciences reaffirmed their commitment to expanding their global footprint through continued investments in quality, systems, and regulatory excellence. The certification is expected to open new opportunities in highly regulated international markets, enhancing the company’s credibility and competitiveness.
